A practical reference on peptide backbone: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-06-21. Anything still debated is marked as such rather than presented as settled.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Many medical procedures are called minimally invasive; those that involve small incisions through which an endoscope is inserted, end in the suffix -oscopy, such as endoscopy, laparoscopy, arthroscopy. Other examples of minimally invasive procedures include the use of hypodermic injection, and air-pressure injection, subdermal implants, refractive surgery, percutaneous surgery, cryosurgery, microsurgery, keyhole surgery, endovascular surgery using interventional radiology (such as angioplasty or embolization), coronary catheterization, permanent placement of spinal and brain electrodes, stereotactic surgery, the Nuss procedure, radioactivity-based medical imaging methods, such as gamma camera, positron emission tomography and SPECT (single photon emission tomography). Related procedures are image-guided surgery, and robot-assisted surgery.
Like the other carbon–halogen bonds, the C–Br bond is a common functional group that forms part of core organic chemistry. Formally, compounds with this functional group may be considered organic derivatives of the bromide anion. Due to the difference of electronegativity between bromine (2.96) and carbon (2.55), the carbon atom in a C–Br bond is electron-deficient and thus electrophilic. The reactivity of organobromine compounds resembles but is intermediate between the reactivity of organochlorine and organoiodine compounds. For many applications, organobromides represent a compromise of reactivity and cost. Organobromides are typically produced by additive or substitutive bromination of other organic precursors. Bromine itself can be used, but due to its toxicity and volatility, safer brominating reagents are normally used, such as N-bromosuccinimide. The principal reactions for organobromides include dehydrobromination, Grignard reactions, reductive coupling, and nucleophilic substitution. Organobromides are the most common organohalides in nature, even though the concentration of bromide is only 0.3% of that for chloride in sea water, because of the easy oxidation of bromide to the equivalent of Br+, a potent electrophile. The enzyme bromoperoxidase catalyses this reaction. The oceans are estimated to release 1–2 million tons of bromoform and 56,000 tons of bromomethane annually.
=== Labour Party organiser === Galloway joined the Labour Party Young Socialists aged 13, having falsely claimed to have been 15, and was still a teenager when he became secretary of the Dundee Labour Party. Galloway became vice-chairman of the Labour Party in the City of Dundee and a member of the Scottish Executive Committee in 1975. On 5 May 1977, he contested his first election campaign in the Scottish district elections, but failed to hold the safe Labour Gillburn ward in Dundee, being defeated by the independent Bunty Turley. He became the secretary organiser of the Dundee Labour Party in 1977, and at 26, was the youngest ever chairman of the Scottish Labour Party in March 1981, a post he held for a year, after holding the vice-chairman post over the previous year. After a trip to Beirut, Lebanon, during 1977, Galloway became a supporter of Palestine, stating during his libel case against The Daily Telegraph in 2004 that "barely a week after my return I made a pledge, in the Tavern Bar in Dundee's Hawkhill District, to devote the rest of my life to the Palestinian and Arab cause." He supported Dundee City Council when it flew the Palestinian flag over the City Chambers building, and was involved in the twinning of Dundee with the Palestinian West Bank town of Nablus in 1980. In late 1981, in an interview for the Scottish Marxist, Galloway supported the affiliation of the Communist Party of Great Britain (CPGB) to the Labour Party, in the same way as the Fabian Society does.
== Pathology == A number of inherited diseases involve defects in carrier proteins in a particular substance or group of cells. Cysteinuria (cysteine in the urine and the bladder) is such a disease involving defective cysteine carrier proteins in the kidney cell membranes. This transport system normally removes cysteine from the fluid destined to become urine and returns this essential amino acid to the blood. When this carrier malfunctions, large quantities of cysteine remain in the urine, where it is relatively insoluble and tends to precipitate. This is one cause of urinary stones. Some vitamin carrier proteins have been shown to be overexpressed in patients with malignant disease. For example, levels of riboflavin carrier protein (RCP) have been shown to be significantly elevated in people with breast cancer.
Sources: en.wikipedia.org
==== Transistors ==== Bismuth-based materials have been claimed to enable smaller, faster, and more energy-efficient transistors than traditional silicon. Bismuth offers a small bandgap and high electron mobility. It has topological insulator states, conducting along its surface/edges while still insulating internally. Two-dimensional semiconductor (2D) materials can be produced from it, enabling thinner and higher-performance devices. Such 2D bismuth materials support subnanometer channel lengths, surpassing silicon's practical limits. However, bismuth's anisotropic heat transport can complicate chip design. Bismuth telluride (Bi2Te3) has been investigated for use in thermoelectric transistors that use temperature gradients (e.g., via laser illumination) to generate electricity, yielding 0.7093 μW in experimental setups. They operate by leveraging the Seebeck effect, using a temperature difference to drive charge carrier movement. Bismuth oxyselenides (Bi2O2Se and Bi2SeO5) have been investigated for use in field-effect transistors (FETs). These 2D materials exhibit high electron mobility (e.g., 10–15 cm2/(V·s)) and stability in air. One study reported that these materials enabled transistors that were 40% faster and 10% more efficient than Intel's 3 nm chips. Bismuth can reduce contact resistance when paired with 2D semiconductors such as MoS2. This eliminates the Schottky barrier—a common efficiency issue in metal-semiconductor interfaces.
Selegiline is available in forms for use by multiple different routes of administration and its pharmacokinetics vary by route. The bioavailability of the oral form of selegiline is 4–10%, of the ODT is 5 to 8 times that of the oral form, and of the transdermal patch is 75%. The time to peak levels of selegiline with oral administration is about 0.5 to 1.5 hours. The plasma protein binding of selegiline is 85–90%. It is metabolized extensively in the liver by the cytochrome P450 enzyme CYP2B6 among other enzymes. Metabolites of selegiline include desmethylselegiline (DMS), levomethamphetamine (L-MA), and levoamphetamine (L-A). The oral form of selegiline is subject to strong first-pass metabolism and levels of the metabolites of selegiline are much lower with the ODT and transdermal patch forms than with the oral form. The elimination half-lives of selegiline and its metabolites range from 1.2 to 10 hours for selegiline, 2.2 to 9.5 hours for DMS, 14 to 21 hours for levomethamphetamine, and 16 to 18 hours for levoamphetamine. Selegiline and its metabolites are eliminated mainly in urine (87% in urine and 15% in feces via oral administration), with its metabolites accounting for virtually all of the eliminated material in the case of the oral form. Hepatic impairment and renal impairment have been found to dramatically increase exposure to selegiline.
The Treuhand's operations drew criticism for unnecessarily closing allegedly profitable businesses, misuse and waste of funds, and layoffs that were claimed to be unnecessary. It also drew substantial protest from the workforces affected, as 2.5 million employees in state-owned enterprises (out of 4 million in total) were laid off in the early 1990s. Supporters argued that not placing the former state-owned enterprises into private hands would have caused the loss of many more jobs and slowed economic recovery. On 1 April 1991, chairman of the Treuhand Detlev Karsten Rohwedder was shot dead by an unknown assassin (possibly the Red Army Faction). He was succeeded by Birgit Breuel. The trust itself was extraordinarily unprofitable, such that, when its operations ended in 1994, it had amassed 260 to 270 billion DM in debt, equal to around 350 billion United States dollars in 2025.
== Description == Buckwheat is a herbaceous annual flowering plant growing to about 60 centimetres (24 in), with red stems and pink and white flowers resembling those of knotweeds. The leaves are arrow-shaped and the fruits are achenes about 5–7 mm with 3 prominent sharp angles. Fagopyrum esculentum is native to south-central China and Tibet, and has been introduced into suitable climates across Eurasia, Africa and the Americas.
== See also == Ventrolateral preoptic nucleus Periventricular nucleus Copeptin Hypothalamic–pituitary–adrenal axis (HPA axis) Hypothalamic–pituitary–gonadal axis (HPG axis) Hypothalamic–pituitary–thyroid axis (HPT axis) Incertohypothalamic pathway Neuroendocrinology Neuroscience of sleep
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.